BCHE and myasthenia gravis: Compared with other subgroups of MG, patients with MuSK-Ab exhibit a poorer response to cholinesterase inhibitors and depend more on steroids while responding better with rituximab, which contributes to more tolerance for the reduction in oral immunosuppressants and corticosteroids (1–5).